| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Oncology and Radiotherapy, Department of Nuclear Medicine, Turku University Central Hospital, Turku Medical Cyclotron-PET Center, Radio Chemistry Laboratory, Turku University, Turku, Finland
Correspondence: For correspondence or reprints contact Paula Lindholm, MD, Department of Oncology and Radiotherapy, Turku University Central Hospital, SF-20520 Turku, Finland.
ABSTRACT
Radiolabeled [18F]-2-fluoro-2-deoxy-D-glucose (FDG) is a glucose analogue widely used to study tumor metabolism by means of positron emission tomography (PET). Little is known about the effect of hyperglycemia on FDG uptake and PET imaging of tumors. Five patients with head and neck cancer underwent two PET studies prior to cancer therapy, first in the fasting state and then 2–5 days later after oral glucose loading. FDG uptake was measured with standardized uptake values (SUV) and Ki values according to Patlak et al. The fasting SUVs ranged from 4.1 to 10.9 and Kis from 0.021 min–1 to 0.067 min–1, whereas after loading both the SUVs (range 2.2–5.9, p < 0.02) and Ki values (range 0.006–0.042 min–1, p < 0.05) decreased significantly, and the quality of the PET images became markedly poorer. The FDG metabolic rate (Ki x P-Gluc) remained similar in different plasma glucose concentrations in tumors, but increased clearly in muscles after loading. Therefore, patients entering PET-FDG studies should fast and their blood glucose concentration needs to be taken into account when evaluating FDG accumulation.
This article has been cited by other articles:
|
|
 |
|
  H. Nomori, T. Mori, K. Ikeda, K. Kawanaka, S. Shiraishi, K. Katahira, and Y. Yamashita Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 816 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Fueger, J. Czernin, I. Hildebrandt, C. Tran, B. S. Halpern, D. Stout, M. E. Phelps, and W. A. Weber Impact of Animal Handling on the Results of 18F-FDG PET Studies in Mice J. Nucl. Med., June 1, 2006; 47(6): 999 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Nomori, N. Kosaka, K. Watanabe, T. Ohtsuka, T. Naruke, T. Kobayashi, and K. Uno 11C-Acetate Positron Emission Tomography Imaging for Lung Adenocarcinoma 1 to 3 cm in Size With Ground-Glass Opacity Images on Computed Tomography Ann. Thorac. Surg., December 1, 2005; 80(6): 2020 - 2025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-y. O. Wong, J. Thie, K. J. Parling-Lynch, D. Zakalik, J. H. Margolis, M. Gaskill, J. Hill, F. Qing, D. Fink-Bennett, and C. Nagle Glucose-Normalized Standardized Uptake Value from 18F-FDG PET in Classifying Lymphomas J. Nucl. Med., October 1, 2005; 46(10): 1659 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nomori, K. Watanabe, T. Ohtsuka, T. Naruke, K. Suemasu, and K. Uno Visual and Semiquantitative Analyses for F-18 Fluorodeoxyglucose PET Scanning in Pulmonary Nodules 1 cm to 3 cm in Size Ann. Thorac. Surg., March 1, 2005; 79(3): 984 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Khan, N Oriuchi, T Higuchi, H Zhang, and K Endo PET in the follow-up of differentiated thyroid cancer Br. J. Radiol., October 1, 2003; 76(910): 690 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Torizuka, T. Kanno, M. Futatsubashi, H. Okada, E. Yoshikawa, F. Nakamura, M. Takekuma, M. Maeda, and Y. Ouchi Imaging of Gynecologic Tumors: Comparison of 11C-Choline PET with 18F-FDG PET J. Nucl. Med., July 1, 2003; 44(7): 1051 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. de Boer, J. Pruim, B. F.A.M. van der Laan, T. H. Que, A. T.M. Willemsen, F. W.J. Albers, and W. Vaalburg L-1-11C-Tyrosine PET in Patients with Laryngeal Carcinomas: Comparison of Standardized Uptake Value and Protein Synthesis Rate J. Nucl. Med., March 1, 2003; 44(3): 341 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Kalady, B. M. Clary, L. A. Clark, M. Gottfried, E. M. Rohren, R. E. Coleman, T. N. Pappas, and D. S. Tyler Clinical Utility of Positron Emission Tomography in the Diagnosis and Management of Periampullary Neoplasms Ann. Surg. Oncol., October 1, 2002; 9(8): 799 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Nabi and J. M. Zubeldia Clinical Applications of 18F-FDG in Oncology J. Nucl. Med. Technol., March 1, 2002; 30(1): 3 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. H. Kernstine, K. A. McLaughlin, Y. Menda, N. P. Rossi, D. J. Kahn, D. L. Bushnell, M. M. Graham, C. K. Brown, and M. T. Madsen Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer? Ann. Thorac. Surg., February 1, 2002; 73(2): 394 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Sutinen, S. Jyrkkio, M. Varpula, P. Lindholm, T. Gronroos, P. Lehikoinen, M. Teras, and H. Minn Nodal Staging of Lymphoma with Whole-Body PET: Comparison of [11C]Methionine and FDG J. Nucl. Med., December 1, 2000; 41(12): 1980 - 1988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. Patz Jr 1999 Plenary Session: Friday Imaging Symposium : Evaluation of Focal Pulmonary Abnormalities with FDG PET RadioGraphics, July 1, 2000; 20(4): 1182 - 1185. [Full Text] [PDF]
|
|
|
|
|
|
P. D. Shreve, Y. Anzai, and R. L. Wahl Pitfalls in Oncologic Diagnosis with FDG PET Imaging: Physiologic and Benign Variants RadioGraphics, January 1, 1999; 19(1): 61 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Romer, A.-R. Hanauske, S. Ziegler, R. Thodtmann, W. Weber, C. Fuchs, W. Enne, M. Herz, C. Nerl, M. Garbrecht, et al. Positron Emission Tomography in Non-Hodgkin's Lymphoma: Assessment of Chemotherapy With Fluorodeoxyglucose Blood, June 15, 1998; 91(12): 4464 - 4471. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
